Background: The prevalence of atrial fibrillation (AF) in ischaemic stroke is estimated at approximately 30%. Proportion of patients with ischaemic stroke and known AF who are prescribed anticoagulation is an accepted quality metric (NHS) for anticoagulation in the community. We aimed to quantify changes in the proportion of anticoagulated patients and those prescribed DOACs who presented with ischaemic stroke and previously known AF to our institution between 2013 and 2016.
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Methods: The National Stroke Register was used to identify all patients admitted to our institution between 2013-2016 with ischaemic stroke and AF. For each year, the proportion of patients on anticoagulation (overall) and DOACs was calculated. Primary endpoint was the change in proportion of patients prescribed anticoagulation prior to stroke. The secondary endpoint was proportion of ischaemic strokes attributable to AF. We performed a Chi Square test to assess statistical significance. Results: A total of 522 patients presented to our institution with ischaemic stroke, of which 22% were known to have AF. The proportion of patients anticoagulated increased from 50% in 2013 to 76% in 2016, (p = 0.043). The proportion of patients on DOACs increased from 8% to 58%, (p = 0.0069). There was a downward trend in proportion of ischaemic strokes attributable to AF (39% -2013 AF (39% - , 37% -2014 AF (39% - , 36% -2015 AF (39% - and 33% -2016 however this wasn't significant (p = 0.84). Conclusion: The audit quantifies the paradigm shift in OAC prescribing since the introduction of DOACs which has led to an overall increase in the proportion of people with AF being anticoagulated. It may also be associated with a decrease in the proportion of ischaemic strokes attributable to AF which requires a larger sample to adequately test. In our opinion, the ease of anticoagulation with DOACs, along with the associated increased focus on stroke prevention with DOAC marketing have contributed.
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